[go: up one dir, main page]

WO2015032841A3 - Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease - Google Patents

Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease Download PDF

Info

Publication number
WO2015032841A3
WO2015032841A3 PCT/EP2014/068782 EP2014068782W WO2015032841A3 WO 2015032841 A3 WO2015032841 A3 WO 2015032841A3 EP 2014068782 W EP2014068782 W EP 2014068782W WO 2015032841 A3 WO2015032841 A3 WO 2015032841A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
methods
mediated disease
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/068782
Other languages
French (fr)
Other versions
WO2015032841A2 (en
Inventor
Laurent Baud
Emmanuel LETAVERNIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Universite Pierre et Marie Curie
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Universite Pierre et Marie Curie
Publication of WO2015032841A2 publication Critical patent/WO2015032841A2/en
Publication of WO2015032841A3 publication Critical patent/WO2015032841A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rehabilitation Therapy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for the prevention or treatment of Th 17 mediated disease.
PCT/EP2014/068782 2013-09-05 2014-09-04 Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease Ceased WO2015032841A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306216 2013-09-05
EP13306216.6 2013-09-05

Publications (2)

Publication Number Publication Date
WO2015032841A2 WO2015032841A2 (en) 2015-03-12
WO2015032841A3 true WO2015032841A3 (en) 2015-05-28

Family

ID=49150890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/068782 Ceased WO2015032841A2 (en) 2013-09-05 2014-09-04 Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease

Country Status (1)

Country Link
WO (1) WO2015032841A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066098A2 (en) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Therapeutic uses of ppar mediators
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
EP1704857A1 (en) * 2004-01-15 2006-09-27 ASKA Pharmaceutical Co., Ltd. Abca1 stabilizer
WO2009055538A1 (en) * 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
US20090203689A1 (en) * 2008-02-07 2009-08-13 Arvinder Dhalla Abca-1 elevating compounds and methods
US20130065911A1 (en) * 2011-09-12 2013-03-14 Uwe Grether N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066098A2 (en) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Therapeutic uses of ppar mediators
EP1704857A1 (en) * 2004-01-15 2006-09-27 ASKA Pharmaceutical Co., Ltd. Abca1 stabilizer
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
WO2009055538A1 (en) * 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
US20090203689A1 (en) * 2008-02-07 2009-08-13 Arvinder Dhalla Abca-1 elevating compounds and methods
US20130065911A1 (en) * 2011-09-12 2013-03-14 Uwe Grether N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PURANIK ET AL: "Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 196, no. 1, 27 June 2007 (2007-06-27), pages 240 - 247, XP022416026, ISSN: 0021-9150, DOI: 10.1016/J.ATHEROSCLEROSIS.2007.05.008 *
QUENTIN RAIMBOURG ET AL: "The Calpain/Calpastatin System Has Opposing Roles in Growth and Metastatic Dissemination of Melanoma", PLOS ONE, vol. 8, no. 4, 2 April 2013 (2013-04-02), pages e60469, XP055084604, DOI: 10.1371/journal.pone.0060469 *
S. D. NANDEDKAR ET AL: "D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma", THE JOURNAL OF LIPID RESEARCH, vol. 52, no. 3, 3 December 2010 (2010-12-03), pages 499 - 508, XP055084597, ISSN: 0022-2275, DOI: 10.1194/jlr.M012724 *
X. YAO ET AL: "5A, an Apolipoprotein A-I Mimetic Peptide, Attenuates the Induction of House Dust Mite-Induced Asthma", THE JOURNAL OF IMMUNOLOGY, vol. 186, no. 1, 29 November 2010 (2010-11-29), pages 576 - 583, XP055084522, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001534 *

Also Published As

Publication number Publication date
WO2015032841A2 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
IL276153B (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency .
EP3448874A4 (en) Compositions for the treatment of disease
EP3448987A4 (en) Compositions for the treatment of disease
EP3318564A3 (en) Bicyclic heterocycles as fgfr inhibitors
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2015085318A3 (en) Targeted adaptive vaccines
WO2016011222A3 (en) Circular polynucleotides
WO2014130856A3 (en) Treatment of skeletal-related disorders
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
HK1243935A1 (en) Organic compounds
WO2014151456A3 (en) Treatment of inflammatory diseases
HK1204928A1 (en) Inhibitors of the notch signalling pathway and secretion for use in medicine
EP4218736A3 (en) Compositions comprising 15-hepe
WO2015092810A3 (en) Amorphous form of idelalisib
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3522873A4 (en) Compositions and methods for the treatment of xerostomia
EP3288636A4 (en) Compositions for the treatment of epistaxis
WO2015080980A3 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
HK1243936A1 (en) Organic compounds
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
WO2016109002A3 (en) Methods and compositions for the treatment of radiation-related disorders
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
WO2016069542A3 (en) Lactone compounds and methods of making and using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14766927

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14766927

Country of ref document: EP

Kind code of ref document: A2